Cycloph 500 mg/vial (IV Infusion)
500 mg vial: ৳ 450.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Cyclophosphamide |
| Company | Eskayef pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of malignant lymphomas
- Hodgkin's disease treatment
- Treatment for multiple myeloma
- Treatment for leukemias
- Treatment for mycosis fungoides
- Treatment for neuroblastoma
- Treatment for ovarian adenocarcinoma
- Treatment for retinoblastoma
- Treatment for breast carcinoma
- Biopsy proven 'minimal change' nephrotic syndrome in children
- Use in carefully selected cases of biopsy-proven 'minimal change' nephrotic syndrome in children
- Mode of action involving cross-linking of tumor cell DNA
- Effective oncolytic drug therapy
- Oral administration with bioavailability greater than 75%
- Elimination half-life of 3 to 12 hours
- Eliminated primarily in the form of metabolites
- Cytotoxic and noncytotoxic metabolites identified in urine and plasma
- High plasma protein binding of metabolites
- Metabolites reach maximum concentration in plasma 2 to 3 hours post intravenous dose
- Dose adjustments based on leukocyte count
- Reduction in dose necessary in combined cytotoxic regimens
- Dialyzable drug and metabolites
- No consistent evidence for dosage modification in renal function impairment
- Increased metabolism and leukopenic activity with phenobarbital
- Concurrent use with other cytotoxic drugs
- Marked and persistent inhibition of cholinesterase activity
- Interaction with succinylcholine chloride
- Contraindicated in severely depressed bone marrow function
- Contraindicated in case of previous hypersensitivity
- Common side effects: nausea, vomiting, anorexia
- Less frequent side effects: abdominal discomfort, diarrhea
- Occasional skin rash and alopecia
- Occasional hematologic effects: leukopenia, thrombocytopenia, anemia
- Hemorrhagic ureteritis and renal tubular necrosis in urinary system
- Interactions leading to interstitial pneumonitis
- Adverse effects on pregnancy and lactation
- Special attention in patients with leukopenia, thrombocytopenia, or impaired hepatic/renal function
- Similar safety profile in pediatric patients
- Varying response in geriatric patients
- Elderly patients may be more susceptible to toxicities
- No specific antidote for overdose
- Cytotoxic chemotherapy
- Storage conditions: temperature not exceeding 25°C, protect from light and moisture, do not freeze